AlzProtect SAS
🇫🇷France
A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
Phase 2
Completed
- Conditions
- Progressive Supranuclear Palsy
- Interventions
- Drug: Placebo oral solutionDrug: AZP2006 oral solution
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AlzProtect SAS
- Target Recruit Count
- 36
- Registration Number
- NCT04008355
- Locations
- 🇫🇷
Hôpital Salengro, Lille, Hauts De France, France
🇫🇷Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Paris, Ile-de-France, France
🇫🇷Hôpital de la Fondation Adolphe de Rothschild, Paris, France
© Copyright 2025. All Rights Reserved by MedPath